HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
Clinical trial NCT06187961 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06187961
- Sponsor
- Tongji Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-30
- Primary completion
- 2026-07-20
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.